Zura Bio Limited Class A Ordinary Shares (ZURA) - Net Assets
Based on the latest financial reports, Zura Bio Limited Class A Ordinary Shares (ZURA) has net assets worth $118.44 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($143.94 Million) and total liabilities ($25.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ZURA goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $118.44 Million |
| % of Total Assets | 82.29% |
| Annual Growth Rate | 7.11% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 109.05 |
Zura Bio Limited Class A Ordinary Shares - Net Assets Trend (2021–2024)
This chart illustrates how Zura Bio Limited Class A Ordinary Shares's net assets have evolved over time, based on quarterly financial data. See Zura Bio Limited Class A Ordinary Shares defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zura Bio Limited Class A Ordinary Shares (2021–2024)
The table below shows the annual net assets of Zura Bio Limited Class A Ordinary Shares from 2021 to 2024. For live valuation and market cap data, see Zura Bio Limited Class A Ordinary Shares market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $160.02 Million | +101.15% |
| 2023-12-31 | $79.55 Million | +460.68% |
| 2022-12-31 | $-22.06 Million | -116.94% |
| 2021-12-31 | $130.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zura Bio Limited Class A Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14671563400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Components | $302.70 Million | 206.18% |
| Total Equity | $146.81 Million | 100.00% |
Zura Bio Limited Class A Ordinary Shares Competitors by Market Cap
The table below lists competitors of Zura Bio Limited Class A Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HansBiomed Corporation
KQ:042520
|
$235.43 Million |
|
Hunan Copote Science Technology Co Ltd
SHG:600476
|
$235.46 Million |
|
LiveWire Group Inc.
NYSE:LVWR
|
$235.48 Million |
|
Soosan Industries Co. Ltd.
KO:126720
|
$235.59 Million |
|
Hwacom Systems
TWO:6163
|
$235.25 Million |
|
Firich Enterprises Co Ltd
TWO:8076
|
$235.22 Million |
|
Alro Slatina
RO:ALR
|
$235.19 Million |
|
Ege Gubre Sanayi AS
IS:EGGUB
|
$235.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zura Bio Limited Class A Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 59,330,000 to 146,815,000, a change of 87,485,000 (147.5%).
- Net loss of 52,403,000 reduced equity.
- New share issuances of 60,757,000 increased equity.
- Other factors increased equity by 79,131,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-52.40 Million | -35.69% |
| Share Issuances | $60.76 Million | +41.38% |
| Other Changes | $79.13 Million | +53.9% |
| Total Change | $- | 147.45% |
Book Value vs Market Value Analysis
This analysis compares Zura Bio Limited Class A Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.85x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.48x to 1.85x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $7.55 | $3.62 | x |
| 2022-12-31 | $-1.86 | $3.62 | x |
| 2023-12-31 | $1.79 | $3.62 | x |
| 2024-12-31 | $1.96 | $3.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zura Bio Limited Class A Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-35.69%) is below the historical average (-32.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 6.46% | 0.00% | 0.00x | 1.08x | $-4.60 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.53 Million |
| 2023 | -101.74% | 0.00% | 0.00x | 1.70x | $-66.29 Million |
| 2024 | -35.69% | 0.00% | 0.00x | 1.22x | $-67.08 Million |
Industry Comparison
This section compares Zura Bio Limited Class A Ordinary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zura Bio Limited Class A Ordinary Shares (ZURA) | $118.44 Million | 6.46% | 0.22x | $235.38 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 … Read more